New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MEDI;PFE;CELG;PRXL;ACOR;NPSP;ALKS;AZN;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
October 24, 2014
09:18 EDTNPSPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Microsoft (MSFT), up 4.3%... KLA-Tencor (KLAC), up 8.8%... Rubicon Project (RUBI), up 17.8%... Gigamon (GIMO), up 16%. ALSO HIGHER: Procter & Gamble (PG), up 2.7% after earning report, announcing plans to exit Duracell business by creating a stand-alone Duracell company... Vitae Pharmaceuticals (VTAE), up 40% following its report of top-line results from two Phase 1 clinical trials... Digital River (DRIV), up 47% after agreeing to be acquired by investor group for $26.00 per share. LOWER: Amazon (AMZN), down 9.3%, downgraded at Cowen and Janney Capital following the company's Q3 report... DryShips (DRYS), down 26% after filing an automatic common stock shelf... NPS Pharmaceuticals (NPSP), down 4.4% following PDUFA date for Natpara extended three months to January 24... Abercrombie & Fitch (ANF), down 4% after downgraded at Goldman and BMO Capital. DOWN AFTER EARNINGS: Pandora (P), down 7%... Synaptics (SYNA), down 9.9%... Flowserve (FLS), down 5%... New Oriental Education (EDU), down 4%.
09:09 EDTNPSPNPS Pharmaceuticals worst case scenario unlikely, says BofA/Merrill
Subscribe for More Information
08:41 EDTNPSPNPS Pharmaceuticals downgraded to Neutral from Buy at Goldman
Subscribe for More Information
07:19 EDTCELGCelgene pipeline could double market cap in 3-5 years, says Deutsche Bank
Deutsche Bank raised its price target for Celgene shares to $134 from $115 following the company's Q3 results saying its pipeline could potentially double the market capitalization over the next 3-5 years. Deutsche views Celgene's pipeline as "the most transformative in biotech" and keeps a Buy rating on the stock.
07:18 EDTCELGCelgene price target raised to $117 from $104 at JMP Securities
Subscribe for More Information
07:13 EDTCELGCelgene price target raised to $119 from $99.50 at Citigroup
Citigroup raised its price target for Celgene shares to $119 following the company's Q3 results on expectations Revlimid will continue to drive growth. It keeps a Buy rating on the stock.
06:53 EDTCELGCelgene price target raised to $120 from $105 at Cantor
Subscribe for More Information
06:49 EDTPFE, AZNPfizer repurchase could squash AstraZeneca bid goal, Reuters says
Subscribe for More Information
05:54 EDTNPSPStocks with implied volatility movement; NPSP HLF
Subscribe for More Information
October 23, 2014
18:52 EDTPFE, NPSPOn The Fly: After Hours Movers
UP AFTER EARNINGS: Rubicon Project (RUBI), up 19.2%... KLA-Tencor (KLAC), up 15.8%... Gigamon (GIMO), up 13.5%... Maxwell (MXWL), up 11.3%... Qlik Technologies (QLIK), up 9.8%... NetSuite (N), up 5.5%... Microsoft (MSFT), up 3.3%... Juniper Networks (JNPR), reverses in after-hours trading and is up 1.4% after reporting third quarter results and announcing a $1.1B increase to the company's share repurchase authorization. ALSO HIGHER: Vitae Pharmaceuticals (VTAE), up 38.6% following positive top-line results from two Phase 1 clinical trials of BI1181181/VTP-37948... Pfizer (PFE), up 1.8% after announcing a new $11B share repurchase program. DOWN AFTER EARNINGS: Amazon.com (AMZN), down 10.7%... Synaptics(SYNA), down 12.7%... Pandora (P), down 6.8%... Lattice Semiconductor (LSCC), down 5.6%... Maxim Integrated (MXIM), down 5.8%. ALSO LOWER: DryShips (DRYS), down 16.5% after filing an automatic common stock shelf... NPS Pharmaceuticals (NPSP), down 7.9% following PDUFA date for Natpara extended three months to January 24... GoPro (GPRO), down 2.8% after being initiated with an Underperform at Oppenheimer.
18:18 EDTPFEGlenview Capital acquires stake in Actavis, Bloomberg reports
Subscribe for More Information
16:47 EDTNPSPNPS Pharmaceuticals PDUFA date for Natpara extended three months to January 24
NPS Pharmaceuticals reported that the FDA has extended the company’s Prescription Drug User Fee Act, or PDUFA, action date for its Natpara Biologics License Application by three months from October 24 to January 24, 2015. The FDA extended the action date to provide time for a full review of a major amendment; such extensions are provided for by regulation. In addition, the FDA requested that NPS Pharma submit a Risk Evaluation and Mitigation Strategy, or REMS, for Natpara and the company is working to finalize the REMS in advance of the revised PDUFA action date. To date, the FDA has not requested that additional clinical studies be completed prior to the approval of Natpara; however, the company expects a post-approval study commitment. Francois Nader CEO of NPS Pharma said, “We continue to advance our commercial readiness activities and are planning for the launch of Natpara in 2Q15.”
16:17 EDTPFEPfizer announces new $11B share repurchase program
The board of directors also authorized a new $11B share repurchase program to be utilized over time. This new program is in addition to the $1.3B of authorization remaining under the company’s current share repurchase program.
12:20 EDTCELGOn The Fly: Midday Wrap
Subscribe for More Information
10:54 EDTCELGAcceleron, Celgene to present sotatercept prelinical interim clinical data
Acceleron Pharma (XLRN) reported that its collaboration partner, Celgene (CELG), and investigators on the sotatercept program will present sotatercept preclinical and interim clinical data at the American Society of Nephrology Kidney Week 2014. The meeting will be held in Philadelphia on November 11-16. Preliminary data, including safety and effects on hemoglobin, bone density and vascular calcification from the ongoing phase 2a clinical trial of sotatercept will be presented on Thursday, November 13. Additionally, data from preclinical studies will be presented on Friday and Saturday, November 13 and 14.
08:15 EDTPFEPfizer wins SUTENT patent case In Delaware District Court
Pfizer (PFE) announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021. Pfizer filed suit in June 2010 after Mylan (MYL) applied to the U.S. Food and Drug Administration to market a generic version of SUTENT prior to the expiration of the patents covering sunitinib malate and its uses. After a four-day trial, the Court agreed that Mylan infringed the valid patents covering SUTENT.
07:33 EDTCELGCelgene raises FY14 adjusted EPS view to $3.65-$3.70 from $3.60-$3.65
Subscribe for More Information
07:32 EDTCELGCelgene reports Q3 REVLIMID sales $1.3B
Subscribe for More Information
07:32 EDTCELGCelgene reports Q3 adjusted EPS 97c, consensus 95c
Subscribe for More Information
06:51 EDTALKSAlkermes concerns removed with FDA acceptance, says Citigroup
Subscribe for More Information
October 22, 2014
15:37 EDTCELGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Comcast (CMCSA), consensus 71c; Union Pacific (UNP), consensus $1.52; 3M (MMM), consensus $1.96; AbbVie (ABBV), consensus 77c; Celgene (CELG), consensus 95c; Eli Lilly (LLY), consensus 67c; Occidental Petroleum (OXY), consensus $1.57; Caterpillar (CAT), consensus $1.36; Alexion Pharmaceuticals (ALXN), consensus $1.16; Precision Castparts (PCP), consensus $3.32; Raytheon (RTN), consensus $1.60; American Electric Power (AEP), consensus $1.02; Southwest Airlines (LUV), consensus 53c; Lorillard (LO), consensus 90c; T. Rowe Price (TROW), consensus $1.15; Mead Johnson (MJN), consensus 91c; Zimmer Holdings (ZMH), consensus $1.30; Nucor (NUE), consensus 73c; Nielsen (NLSN), consensus 65c; Prologis (PLD), consensus 46c; Sigma-Aldrich (SIAL), consensus $1.06; Under Armour (UA), consensus 40c; EQT (EQT), consensus 56c; Dr Pepper Snapple (DPS), consensus 88c; Cameron International (CAM), consensus $1.10; Coca-Cola Enterprises (CCE), consensus 89c; Quest Diagnostics (DGX), consensus $1.08; CMS Energy (CMS), consensus 41c; Airgas (ARG), consensus $1.29; PulteGroup (PHM), consensus 36c; Diamond Offshore (DO), consensus 79c; Bemis (BMS), consensus 67c.
11:55 EDTCELGStocks with call strike movement; YHOO CELG
Yahoo (YHOO) January 48 call option implied volatility decreased 6% to 32, Celgene (CELG) April 110 call option implied volatility increased 2% to 32 according to IVolatility.
11:38 EDTCELGBiogen retreats after Tecfidera sales miss, patient death reported
Subscribe for More Information
11:01 EDTCELGBiogen trading lower on slower growth, PML case, says Deutsche Bank
Deutsche Bank attributes the pullback in shares of Biogen (BIIB) to slower sequential revenue growth and the one PML case with Tecfidera disclosed on today's earnings call. Deutsche believes investors are now favoring Celgene (CELG) over Biogen due to near term headline risks. The firm says it likes Celgene more as well due its pipeline, but keeps a Buy rating on Biogen.
07:35 EDTAZNCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
07:02 EDTALKSAlkermes aripiprazole lauroxil NDA accepted for filing by FDA
Subscribe for More Information
October 21, 2014
09:48 EDTNPSPShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information
09:23 EDTCELGCelgene GED-0301 said to have 67% 12-week remission at high dose in trial
Subscribe for More Information
07:54 EDTALKSLeerink a buyer of Alkermes, ImmunoGen, Incyte
Subscribe for More Information
07:15 EDTPFE, AZNFDA to hold workshop on breast cancer drug development
Subscribe for More Information
07:06 EDTPFEFierce Biotech to hold a breakfast meeting
Subscribe for More Information
06:10 EDTAZNInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas – influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.
October 20, 2014
13:26 EDTCELGCelgene I&I franchise boosted by Crohn’s trial data, says William Blair
William Blair said it views the preliminary Phase II efficacy and safety data from mongersen in Crohn’s disease reported by Celgene as encouraging. The firm noted that the 10 mg arm did not achieve significance, but the three data points collectively formed a robust dose-response that William Blair said lends support for the drug's proposed mechanism of action. William Blair believes mongersen complements Celgene’s Inflammation & Immunology portfolio and the firm maintains its Outperform rating on the stock, which is up 4% to $91.65 in afternoon trading.
13:21 EDTCELGCelgene reports Phase II data in Crohn’s Disease to be presented at UEG
Subscribe for More Information
09:22 EDTNPSPOn The Fly: Pre-market Movers
Subscribe for More Information
07:47 EDTPFE, AZNPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:19 EDTAZNIBC Life Sciences to hold a conference
Subscribe for More Information
07:15 EDTPFEAmerican Academy of Child & Adolescent Psychiatry to hold annual meeting
Subscribe for More Information
07:14 EDTAZNEuropean College of Neuropsychopharmacology to hold a conference
27th ECNP Congress is being held in Berlin, Germany on October 18-21.
07:12 EDTPFECongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTPFEAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTPFEAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
06:56 EDTNPSPShire reopens acquistion talks with NPS Pharmaceuticals, Cubist, Telegraph says
Subscribe for More Information
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 17, 2014
16:41 EDTPFEPfizer confirms FDA labeling approval for EMBEDA capsules
Pfizer announced that the FDA has approved an updated label for EMBEDA extended-release capsules, for oral use to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal routes when crushed. However, abuse of EMBEDA by these routes is still possible. The updated label also includes data from a human abuse potential study of intravenous, or IV, morphine and naltrexone to simulate crushed EMBEDA. However, it is unknown whether the results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available. EMBEDA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Pfizer expects EMBEDA will be available in the U.S. in early 2015.
16:30 EDTPFEFDA approves new labeling from Embeda extended-release capsules
Subscribe for More Information
13:18 EDTCELGLeerink's biotech analyst holds an analyst/industry conference call
Subscribe for More Information
October 16, 2014
15:10 EDTCELGAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
08:38 EDTPFEBaxter expects divestiture of vaccines business to Pfizer to close in Q4
Subscribe for More Information
08:08 EDTPFEActavis confirms generic Quillivant XR patent challenge
Subscribe for More Information
07:28 EDTPFEFDA to hold a joint advisory committee meeting on Chantix
Subscribe for More Information
October 15, 2014
15:00 EDTPFEShire-Allergan, AbbVie-Pfizer deals possible if merger scrapped, Bloomberg says
Subscribe for More Information
10:48 EDTAZNShire tanks with AbbVie calling board meeting over merger
Subscribe for More Information
October 14, 2014
11:23 EDTTEVA, AZN, PFEBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTTEVATeva upgraded to Buy from Hold at Standpoint Research
07:15 EDTALKSBiotech Industry Organization to hold a summit
Subscribe for More Information
October 13, 2014
10:08 EDTAZNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTPFEPfizer announces FDA acceptance of Palbociclib NDA with priority review
Subscribe for More Information
07:53 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
05:27 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
October 10, 2014
10:01 EDTPRXLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:41 EDTCELGCelgene reports apremilast significantly improved preexisting psoriasis in study
Subscribe for More Information
08:39 EDTCELGCelgene says data show Apremilast treatment resulted in improved quality of life
Subscribe for More Information
08:06 EDTPFEPfizer presents Staphylococcus aureus vaccine Phase 1, Phase 2 study data
Subscribe for More Information
07:57 EDTPRXLPAREXEL downgraded at ISI Group
Subscribe for More Information
06:18 EDTPRXLPAREXEL downgraded to Neutral from Buy at ISI Group
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use